You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Clinical Vector for TCR Immunotherapy Targeted to Melanoma

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( smart pumps ). A proprietary approach is proposed basedon the favorable physico-chemical properties conferred by chloro-aromatic substitutions in the insulin molecule. This Phase 2 SBIR application th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral therapy (HAART). Unfortunately, the rate of new HIV i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Pivotal trial of vamorolone in Duchenne muscular dystrophy

    SBC: ReveraGen BioPharma, Inc.            Topic: NINDS

    Abstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTIONprovided by applicantThe world needs a highly effective malaria vaccineSanaria rPfSPZ Vaccinecomposed of asepticpurifiedcryopreserved radiation attenuated PfSPZprotectedof volunteers in an NIH clinical trialThe vaccine has been administered by direct venous inoculationDVItosubjects in MaliTanzaniaEquatorial GuineaEGand USASafetytolerabilityhigh grade protectionheterologous protection af ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. TB Diagnostics at the Point of Care

    SBC: AKONNI BIOSYSTEMS INC.            Topic: NIAID

    ABSTRACT Tuberculosis ranks in the top ten worldwide cause of death and now ranks ahead of HIV, making it the number one infectious disease killer. Perhaps, most alarming is the global prevalence of multidrug-resistant TB (MDR- TB) and extensively drug-resistant TB (XDR-TB): more than 5% of new TB cases are MDR-TB and 10% of these have XDR-TB. And, the number of enrolled XDR-TB cases has grown fro ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. In Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant Sanariaandapos s platform technology is production of aseptic purified cryopreserved Plasmodium falciparum Pf sporozoites SPZ This technology has produced three products administered by needle and syringe all of which are in clinical trials PfSPZ Vaccine radiation attenuated PfSPZ PfSPZ Challenge infectious PfSPZ for controlled human malaria infec ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Genetically Attenuated PfSPZ Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant We build on the successful work in Phase II SBIR R AI in which a genetically attenuated Plasmodium falciparum Pf parasite GAP was produced and shown to generate aseptic Pf sporozoites SPZ that invade hepatocytes but do not replicate We will use this genetically attenuated double mutant parasite deficient in the genes encoding SLARP and B Pf ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government